The incidence of various cancers has been increasing and cancer is the most deadly disease threatening human life. One of the main causes of deaths is the inherent metastatic property of malignant tumors. This poses great difficulty in developing clinical therapeutics. The multi-linked pathological processes of tumor metastasis include: basement membrane degradation, matrix permeability, forward movement of tumor cells including secondary growth, and interaction between tumor cells and host stromal cells. CD147/EMMPRIN, also known as basigin or M6 antigen, has been shown to play an important role in tumor metastasis by stimulating tumor stromal cells to produce matrix metalloproteinases (MMPs) and degrading basement membrane and stroma[@b1].

CD147/EMMPRIN is a member of the immunoglobulin family and is widely expressed in a variety of human tissues and cells[@b1]. CD147/EMMPRIN functions to: (1) facilitate secretion of MMP-1, MMP-3, MMP-9 and membrane-type 1-MMP from cancer cells, fibroblasts and endometrial cells, leading to degradation of basement membrane and extracellular matrix, thus promoting tumor proliferation, invasion and metastasis[@b1][@b2]; (2) drive tumor angiogenesis by enhancing MMPs and vascular endothelia growth factor (VEGF) levels in cancer cells and the mesenchyme[@b3]; (3) regulate expression and activity of monocarboxylate transporters-1 (MCT-1) and MCT-4, and form complexes on the membrane to transport lactic acid produced by anaerobic glycolysis[@b4]; (4) develop chemoresistance in many cancers, probably by mediating activation of phosphatidylinositol 3-hydroxy kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways[@b5][@b6][@b7][@b8]; and (5) interact with α3β1, α6β1 integrins to regulate adhesion with extracellular matrix proteins, collagen, laminin or fibronectin and also promote expression of cyclophilin A to induce cancer cell proliferation[@b9]. All of these functions are regulated by CD147/EMMPRIN and are summarized in [Fig. 1](#f1){ref-type="fig"}. The outcomes of many of the pathways regulated by CD147 have been associated with the adverse outcomes highlighted in our study.

It is highly upregulated in several malignant tumors[@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17]. A few recent studies[@b10][@b15][@b16][@b17] have revealed a conflicting correlation between CD147/EMMPRIN and various outcomes in different cancers. A meta-analysis of the literature published previously suggests that elevated MCT-4 and CD147 expressions are associated with worse prognosis across many cancer types focusing on the aspect of tumor metabolism while the existing evidence lacks statistical power to draw a convincing conclusion[@b18]. The objective of this updated study was to systematically assemble all the existing CD147 literature, link the data to variable outcomes, perform a comprehensive meta-analysis to predict potential prognostic effects in different cancers, and provide further evidence to establish CD147/EMMPRIN as a key player in tumor progression from a number of perspectives.

Results
=======

Our systematic literature search of CD147 and its correlation with different outcomes identified 910 articles. Among these, 836 articles were excluded and only 82 studies satisfied the inclusion eligibility for the meta-analysis. Upon further review of the full text articles, eight additional articles from reference sources were included. An additional 29 studies were excluded due to the following reasons: two articles were reviews; three were duplicate reports; four had insufficient data; four included only a few cases; nine explored the prognostic value of CD147/EMMPRIN in combination with other biomarkers, such as VEGF, MMP-2, CD44s, MCT-1; and seven studies were determined to be too complicated for subgroup analysis. The remaining 53 studies[@b5][@b6][@b7][@b9][@b10][@b11][@b12][@b13][@b14][@b15][@b16][@b17][@b19][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56][@b57][@b58][@b59] containing 68 datasets that met our inclusion criteria were included in this review ([Fig. 2](#f2){ref-type="fig"}). Among the eligible studies, 33 provided survival information about the correlation of CD147/EMMPRIN expression with tumor prognosis using a multivariate model and 20 presented the same information using a univariate model. The characteristics of these two models are summarized in [Tables 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}, respectively.

The 53 eligible studies represented 26 different carcinomas or sarcomas and a median number of 204.5 patients (range, 40--600). CD147/EMMPRIN expression in these studies was mainly detected by immunohistochemistry (IHC). One publication had three groups of subjects from different cancers and was therefore considered as three different studies[@b49]. Ten publications[@b12][@b13][@b14][@b16][@b25][@b29][@b38][@b39][@b51][@b52] presented two different prognostic results, while one publication[@b31] presented three prognostic results. Some studies also investigated the link between CD147/EMMPRIN and chemotherapy[@b5][@b6][@b7] or radiation resistance[@b57]. In terms of clinicopathological variables, most of the studies suggested that increased CD147/EMMPRIN expression correlated significantly with higher clinical grade, tumor size, invasion depth, lymphatic invasion, histological grade, and some additional parameters ([Table 3](#t3){ref-type="table"}).

CD147/EMMPRIN and overall survival (OS)
---------------------------------------

The 44 studies, with data from a total of 5,813 patients, showed that CD147/EMMPRIN expression was associated with worse OS, both in multivariate (meta-hazard ratio (HR) = 1.92; 95% confidence interval (CI): 1.58--2.32) and in univariate models (meta-HR = 1.98; 95% CI: 1.53--2.57) ([Table 4](#t4){ref-type="table"}; [Fig. 3A,B](#f3){ref-type="fig"}). In addition, separate analysis of solid and non-solid tumors suggested that the OS of solid tumors was significantly associated with CD147 in both multivariate (meta-HR = 1.73; 95% CI: 1.44--2.08) and univariate (meta-HR = 2.06; 95% CI: 1.57--2.70) models. In contrast, OS of non-solid tumors only displayed significant association in the multivariate model (meta-HR = 3.72; 95% CI: 2.23--6.22), while there was no significant association in the univariate model analysis (meta-HR = 1.34, 95% CI: 0.77--2.32) ([Table 4](#t4){ref-type="table"}).

Furthermore, the subgroup analysis of tumors stratified by cancer type also demonstrated a significant association between higher CD147/EMMPRIN expression and adverse outcome of OS for breast carcinoma (meta-HR = 2.92; 95% CI: 1.85--4.60), bladder cancer (meta-HR = 2.32; 95% CI: 1.63--3.29), colorectal cancer (meta-HR = 2.14; 95% CI: 1.38--4.26), ovarian cancer (meta-HR = 1.57; 95% CI: 1.23--2.01) and osteosarcoma (meta-HR = 7.83; 95% CI: 3.18--19.27) in the multivariate model. However, an association was only observed in renal cell carcinoma (meta-HR = 1.87; 95% CI: 1.37--2.56) and bladder carcinoma (meta-HR = 2.51; 95% CI: 1.46--4.33), using the univariate model. In contrast, there was no association in gastric carcinoma (meta-HR = 1.33; 95% CI: 0.99--1.80) and lung cancer (meta-HR = 1.16; 95% CI: 0.63--2.12) ([Table 4](#t4){ref-type="table"}). We also found a similar association of CD147 with the adverse outcome (OS) in many other cancers, such as adenoid cystic carcinoma of salivary glands, esophageal squamous cell carcinoma, prostate cancer, pediatric medulloblastoma, glioblastoma, gallbladder carcinoma, nasopharyngeal carcinoma, tongue squamous cell carcinoma, endometrial cancer, uterine cervical carcinoma, hepatocellular carcinoma, pancreatobiliary adenocarcinoma, cutaneous squamous cell carcinoma, astrocytomas and soft tissue sarcomas ([Supplementary Figure 1A,B](#S1){ref-type="supplementary-material"}).

CD147/EMMPRIN and progression free survival (PFS), metastasis-free survival (MFS) and recurrence-free survival (RFS)
--------------------------------------------------------------------------------------------------------------------

Analysis of 19 studies, with a total of 2,472 patients, showed that CD147/EMMPRIN expression was associated with worse PFS/MFS/RFS, both in multivariate (meta-HR = 2.32; 95% CI: 1.67--3.21) and univariate (meta-HR = 2.18; 95% CI: 1.30--3.63) models ([Table 3](#t3){ref-type="table"} and [Fig. 4A,B](#f4){ref-type="fig"}). Moreover, the HR estimates derived specifically from the solid tumors by both models showed a similar pattern of association (multivariate: meta-HR = 2.26; 95% CI: 1.61--3.18; univariate: meta-HR = 2.18; 95% CI: 1.30--3.63). Exclusive analysis of non-solid tumors by a multivariate model suggested a significant association (meta-HR = 3.52; 95% CI: 1.18--10.5) ([Table 4](#t4){ref-type="table"}).

Similarly, the subgroup analysis of tumors stratified by cancer type again demonstrated a significant association between CD147/EMMPRIN overexpression and adverse outcome of PFS/MFS/RFS in breast carcinoma (meta-HR = 2.50; 95% CI: 1.63--3.83) and ovarian cancer (meta-HR = 1.72; 95% CI: 1.23--2.40) in the multivariate model and renal cell carcinoma (meta-HR = 1.58; 95% CI: 1.34--1.85) in the univariate model. Similar associations were observed in hepatocellular carcinoma, bladder cancer, prostate cancer, colorectal cancer, osteosarcoma, gastric cancer and hypopharyngeal squamous cell carcinoma. However, we did not observe an association in cases of endometrial carcinoma, and the results were not consistent for cervical carcinoma ([Supplementary Figure 2A,B](#S1){ref-type="supplementary-material"}).

CD147/EMMPRIN and disease-specific survival (DSS)
-------------------------------------------------

Quantitative analysis of five different studies, representing 1,031 patients, linked CD147/EMMPRIN overexpression with DSS in four different solid tumors, namely breast cancer[@b2], colorectal cancer \[24, 41\], oral squamous cell carcinomas[@b7] and cervical cancer[@b16]. Multivariate model analysis established that CD147/EMMPRIN expression was associated with a worse DSS (meta-HR = 1.83; 95% CI: 1.27--2.65) ([Table 4](#t4){ref-type="table"}; [Fig. 5A](#f5){ref-type="fig"}). Similarly, univariate model analysis indicated that CD147 expression associated with worse DSS (meta-HR = 5.81; 95% CI: 4.16--7.46) ([Table 4](#t4){ref-type="table"}). This pattern was unchanged even in the subgroup analyses stratified by cancer type. Multivariate model analysis also identified the following associations with DSS: breast carcinoma (meta-HR = 1.70; 95% CI: 1.02--2.84), oral squamous cell carcinoma (meta-HR = 3.89; 95% CI: 1.11--13.71) and colorectal cancer (meta-HR = 2.30; 95% CI: 1.03--5.14). The only cancer for which we did not observe an association was uterine cervical carcinoma (meta-HR =1.23; 95% CI: 0.52--2.90) ([Supplementary Figure 4](#S1){ref-type="supplementary-material"}).

CD147/EMMPRIN and chemotherapy drug/radiation resistance
--------------------------------------------------------

Among the included articles, three studies[@b5][@b6][@b7] reported risk for CD147/EMMPRIN overexpression and chemotherapy drug resistance, while only one study[@b57] reported radiation resistance. Quantitative analysis of three articles revealed that positive expression of CD147/EMMPRIN predicted recurrence of drug resistance (meta-OR = 9.30; 95% CI: 2.09--41.30) ([Fig. 5B](#f5){ref-type="fig"}). In addition, CD147/EMMPRIN overexpression appeared to be linked to high risk of radiation resistance (OR = 13.30; 95% CI: 4.38--40.35) in cervical squamous cell carcinomas, although this is just based on one study ([Fig. 5C](#f5){ref-type="fig"}).

Heterogeneity analysis
----------------------

There was evidence of significant heterogeneity (I^2^ \> 50%) between OS and PFS studies, but not among DSS studies ([Table 4](#t4){ref-type="table"}). Therefore, the random-effect model was used in all analyses except for the DSS. For the OS and PFS studies, we conducted a meta-regression analysis using publication year, cancer type, sample size, and country as covariates. All covariates were entered into the meta-regression model simultaneously, and the covariates with the highest p values were omitted one at a time to identify sources of heterogeneity. The meta-regression did not identify any of these covariates as a significant source of heterogeneity for OS and PFS studies in multivariate, and indicated that cancer type may be the source of heterogeneity for OS studies in univariate analysis (Coef = 0.093, p = 0.042) ([Supplementary Figure 4](#S1){ref-type="supplementary-material"}). Meta-regression was not used for univariate analysis of the PFS since these studies numbered less than 10.

Sensitivity analysis
--------------------

We also performed a sensitivity analysis to evaluate the effects of individual studies on the pooled HR estimates by omitting one study at a time. The HR estimates for the DSS and PFS/MFS/RFS in the multivariate model were not altered. However, the HR estimates for the OS in the multivariate model, and OS and PFS/MFS/RFS in the univariate model were altered when one, one and two studies were excluded, respectively (data not shown).

Publication bias
----------------

To assess confidence in our study, we performed a publication bias analysis using the funnel plot and Egger's and Begg's rank correlation tests. There was no significant publication bias in both models for the DSS and PFS/MFS/RFS groups ([Table 4](#t4){ref-type="table"}; [Fig. 6D--F](#f6){ref-type="fig"}). In the case of the OS group, the univariate model ([Table 4](#t4){ref-type="table"}; [Fig. 6C](#f6){ref-type="fig"}) suggested no publication bias, but in the multivariate model, results were inconsistent based on the p value obtained by Begg's rank test (0.05) and Egger's test (0.007) ([Table 4](#t4){ref-type="table"}; [Fig. 6A](#f6){ref-type="fig"}). These test results were nonparametric and therefore the Trim and Fill method was used to further verify this analysis. After filling the deleted studies (square dots), we found no obvious asymmetry in the funnel plot ([Fig. 6B](#f6){ref-type="fig"}). Thus, the HR estimates for the prognostic value of CD147/EMMPRIN were not notably altered (data not shown). This suggests that there was no publication bias even in the OS group in the multivariate model.

Discussion
==========

CD147/EMMPRIN is a glycosylated, multifunctional molecule that participates in tumor progression[@b61]. In the present study, we quantitatively analyzed the data from 53 studies, including 68 datasets, to examine the associations between CD147/EMMPRIN expression and its prognosis predictive value in cancer. Previous studies have suggested that combination of CD147/EMMPRIN with other factors, especially VEGF[@b60][@b62][@b63] and MMP-2[@b64][@b65][@b66], can predict the prognosis of some cancers. Here, we exclusively studied the role of CD147/EMMPRIN in tumor prognosis. Our meta-analysis revealed that the prognosis in three adverse outcomes was significantly poor in cases with CD147/EMMPRIN overexpression. This was further confirmed in subgroup analyses of tumors stratified by cancer type. Meanwhile, the predictive role of CD147/EMMPRIN in cervical cancer and hepatocellular carcinoma prognosis has been controversial and its result in cervical carcinoma, endometrial carcinoma, pancreatobiliary adenocarcinoma and some additional tumors did not consistently reach significance. However, the sample size and studies in our stratified analysis were small, and our findings should be further verified.

CD147/EMMPRIN has been shown to be involved in the regulation of tumor cell invasion, metastasis, angiogenesis, anti-apoptosis, adhesion and facilitation of drug resistance through its association with various proteins[@b1], such as MMP-2[@b19], MMP-9[@b20], Ki-67[@b14], VEGF[@b19], microvessel density[@b19], C-erbB-2[@b12], S100A4[@b31], a disintegrin and metalloproteinase 17[@b32], lewis y antigen[@b6], fascin[@b43], caveolin-1[@b48], hypoxia inducible factor 1 alpha[@b9], cyclophilin A[@b9], CD44v6[@b54], cyclooxygenase-2[@b54], receptor for activated C kinase 1[@b55] and metabolism related factors like MCT-1[@b56], MCT-4[@b56], and glucose transporter -1[@b57]. However, there is some conflicting literature refuting associations with paxillin[@b42], syndecan-1[@b42], and MMP-2 and MMP-9[@b22]. In addition, CD147 expression has been proposed to inversely correlate with estrogen and progesterone expression[@b10][@b12]. Furthermore, CD147/EMMPRIN was positively associated with clinicopathological variables in most studies ([Table 3](#t3){ref-type="table"}). It is speculated that CD147/EMMPRIN interacting with many proteins representing various molecular or biological pathways contributes to malignant progression, eventually causes adverse clinical outcomes.

Previous meta-analyses didn't explore any significant association between CD147/EMMPRIN and susceptibility of radio-chemotherapy. In the view of more studies are warranted to validate CD147/EMMPRIN association with chemotherapy and radiation resistance prediction[@b5][@b6][@b7][@b57]. It has been suggested that chemotherapy drugs combined with CD147-targeted therapy may increase the sensitivity of tumor cells to several different chemotherapeutics, and can result in more effective inhibition of tumor proliferation and recurrence[@b7][@b67]. Our study also established that increased CD147/EMMPRIN expression is linked to high risk of drug resistance and our preliminary analysis linked CD147 to radiation resistance. It follows that CD147/EMMPRIN has been proposed to be an important potential therapeutic target.

The results of the present study must be interpreted with caution due to the presence of substantial heterogeneity. In addition, there were several limitations in this study. First, the composition of the cancer type or stage varied between studies, and the detection and corresponding cut-offs varied. For instance, some studies only included pediatric patients[@b26] while others included older patients[@b10]. Also, in non-small-cell lung cancer, CD147/EMMPRIN was associated with poor survival in patients with adenocarcinoma only, but not with squamous cell carcinoma[@b22]. The scoring criteria were also inconsistent. Second, the follow-up time varied across studies, which may have contributed to the non-homogeneity of prognostic information. Sensitivity analysis results also showed instability within individual articles. Third, this study was based on published articles only and, since negative data are hard to publish, there could be publication bias, which is an inherent limitation of all meta-analyses, irrespective of outcomes from the Egger's linear regression test and Begg's rank correlation test.

Conclusion
==========

In summary, this meta-analysis indicated that higher expression of CD147/EMMPRIN potentially may be a prognostic marker for most cancers, and thus can serve as a potential therapeutic target. We further verified that CD147/EMMPRIN had a complex role in tumor progression by crosstalk with numerous factors. However, additional multicenter prospective studies are warranted to confirm these findings, especially in various types of tumors.

Methods
=======

Study identification
--------------------

We searched PubMed and Embase databases through March 2015 to identify relevant studies for inclusion in our meta-analysis. The following keywords were used in the literature searches; "CD147", "extracellular matrix metalloproteinase inducer", "EMMPRIN", "basigin", "survival", "prognosis", "tumor", "cancer", "carcinoma", "neoplasm", or their combinations. Eligible articles were selected based on title, abstract and full text. If the same patient cohort was reported in multiple publications, only the most complete and most recent publication was selected. We also searched of the reference lists from electronically identified articles.

Inclusion and exclusion criteria
--------------------------------

Based on the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines, we included studies that met all of the following criteria: (1) written in English; (2) reported quantitative outcomes from prognostic association studies of tumor and CD147/EMMPRIN; (3) described outcomes as overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), metastasis-free survival (MFS) or recurrence-free survival (RFS), depending upon the study; (4) had a minimum of 40 case numbers describing prognosis; (5) provided a detailed protocol, including the source of raw materials, methodology, quantification methods, and scoring criteria; (6) precisely defined the time-to-event outcome, time to follow-up, and the median follow-up time; and (8) data were presented as the estimated hazard ratios (HRs) with 95% confidence intervals (CIs) or in the case where HRs or 95% CIs were not reported directly, a calculation was used to determine if the conditions of the study were suitable for inclusion[@b68]. Multivariate analyses were used for statistical analysis biomarkers that had independent prognostic factors for cancers after adjusting for one or more additional standard clinical prognostic variables like age, pathology, stage, grade, lymphatic metastasis or other biological marker variables. Studies were excluded if they were case reports, case-only studies, letters, reviews, reported insufficient data, lacked statistical analysis, combined with other factors, or were duplicate studies. All studies were independently reviewed by two authors, and in a case of conflict a third author resolved the issue after thorough discussion.

Data collection and analysis
----------------------------

We assessed heterogeneity using the Chi[@b2] test and I^2^ test[@b69]. If heterogeneity was present, meta-regression was used to determine the source. We combined data from different trials using a fixed-effect model when there was no significant heterogeneity in populations (I^2^ \< 50%) and a random-effect model when there was considerable heterogeneity. If heterogeneity was present, meta-regression was used to determine the source. Variables were synthesized using HR/OR. By convention, an overall HR (OR) \> 1 with a 95% CI implied a poor outcome (high risk) for the group with either positive or negative biomarker expression. The high HR value corresponded with poor survival. To evaluate the effects of individual studies on the pooled HR estimates, we performed a sensitivity analysis omitting one study at a time. The statistical significance was set at 0.05. We used funnel plot asymmetry using Egger's linear regression test and Begg's rank correlation test to assess the publication bias. If both test results were inconsistent, Nonparametric Trim and Fill method was used to verify the results[@b70]. A P value of \<0.05 suggested significant publication bias. All statistical analyses were performed using STATA 12.0 (StataCorp, College Station, TX) statistical software.
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![Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and overall survival (OS) in cancer patients.\
Panel A, represents the association of CD147/EMMPRIN positive expression with worse OS in multivariate model, while panel B, represents similar association by univariate model.](srep32804-f3){#f3}

![Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and PFS/MFS/RFS in cancer patients.\
Panel (A) represents the overall association of CD147/EMMPRIN positive expression with worse PFS/MFS/RFS in multivariate model; panel (B) depicts similar association in univariate model.](srep32804-f4){#f4}

![Qualitative meta-analysis of the association between CD147/EMMPRIN over-expression and disease free survival (DSS) in cancer patients, and to predict easier recurrence of drug resistance.\
Panel A, represents the association of CD147/EMMPRIN positive expression with worse DSS in multivariate model. Panels B, represents the potential of CD147/EMMPRIN positive expression to predict easier recurrence of drug resistance.](srep32804-f5){#f5}

![Assessment of publication bias for OS, DSS, and PFS/MFS/RFS studies.\
Panel (A) depicts the assessment of publication bias for multivariate model studies, by funnel plot analysis, whereas panel (B) shows funnel plot analysis using nonparametric Trim and Fill method. Panel (C) represents the publication bias in univariate model studies. Panel (D) represents the assessment of publication bias for multivariate model. Panels (E,F) represents assessment of publication bias for multivariate and univariate model studies, respectively.](srep32804-f6){#f6}

###### Characteristics of studies exploring the relationship between CD147/EMMPRIN expression and tumor prognosis (Multivariate model).

  Author                     Year   Country                    Cancer type                          Stage/grade          Number Median (range)               Age               Follow-up time Median (range)   Detection method       Cut-off          Outcome
  ------------------------- ------ ---------- --------------------------------------------- --------------------------- ----------------------- ----------------------------- ------------------------------- ------------------ ------------------ --------------
  Natalie Reimers-10         2004   Germany                 Breast carcinoma                          pT1-pT4                     600                       \>50y                      63m (1--176m)               TMA/IHC           score ≥ 1           DSS
  HC Zheng-19                2006    Japan                  Gastric carcinoma                          0--IV                      219                  66.8y (38--88y)              40.4m (0.2m--12.2y)            TMA/IHC              ≥5%               OS
  Kazu Ueda-20               2006    Japan                Endometrial carcinoma                        I--IV                      112                    55.3 ± 11.7                        NA                       IHC             score \> 2          RFS
  Qing Zhang-21              2007    China              Hepatocellular carcinoma                       I--IV                      111              47.47 ± 9.55 (24--66y)             26m (30--1880d)                IHC                ≥1%              RFS
  Anne B. Als-5              2007   Denmark                  Bladder Cancer                       T4b, N2--3, M1                  124                  62.6y (31--78y)             56.5 (19.5--129.8) m              IHC          κ values of 0.83        OS
  Wulf Sienel-22             2008   Germany            Non-small-cell lung cancer                     T1--T4                      57                    60y (37--80y)                  36 m (4--156)                 IHC           score  \> 200          OS
  Xingzhu Ju-23              2008    China                   Cervical Cancer                         Ib2--IIb                     75                   49.7y (21--72y)                 52m (3--168m)                 IHC                ≥1%              DSS
  Yu Li-11                   2009    China                  Breast carcinoma                       infiltrating                   106                        NA                       63.5m (7--170)               TMA/IHC              ≥30%             RFS
  Fangfang Liu-12            2010    China                  Breast carcinoma                         Invasive                     186                  52.5y (23--85y)                64.8m (7--170m)                IHC                ≥1%            OS, PFS
  Xinjie Yang-24             2010    China     Adenoid cystic carcinoma of salivary glands             I--IV                      72                         NA                 76.76 ± 37.47 m; (9--178 m)          IHC                ≥5%               OS
  Wei-De Zhong-25            2010    China                   Bladder cancer                           T1--T4                      101                  68.1y (46--82y)                      36m                      IHC                ≥5%            OS, PFS
  Tongwei Chu-26             2011    China              Pediatric Medulloblastoma            M0--M4 (Metastatic stage)            56                 Paediatric patients                   5--y                      IHC                ≥5%               OS
  Yijun Xue-27               2011    China                   Bladder cancer                          pT1--pT4                     108                  58.3y (31--82y)                35.5 m (3--86m)              TMA/IHC              ≥1%               OS
  Shaojun Zhu-28             2011    China         Esophageal Squamous Cell Carcinoma                   NA                        86                       40--78y                        4--6 y                     IHC                ≥5%               OS
  Weide Zhong-29             2011    China                   Prostate cancer                         pT2--pT3                     240            61.81 ± 6.54y/61.94 ± 5.83y                NA                     TMA/IHC              ≥5%            MFS, OS
  Xuecheng Bi-30             2012    China                   Human seminomas                         pT1--pT4                     65                   21.66 ± 10.18y                       5 y                      IHC                ≥5%               OS
  K Boye-31                  2012    Norway                 Colorectal cancer                         I--III                      242                  70y (21--98 y)                9.1y (8.2--10.0y)               IHC                ≥5%          MFS, DSS, OS
  Zhangxuan Shou-32          2012    China                   Gastric Cancer                            I--IV                      436                   64y (30--91y)                      \>5y                    TMA/IHC              ≥5%               OS
  Albrecht Stenzinger -33    2012   Germany                 Colorectal cancer                          I--IV                      285                       66.6y                           NA                     TMA/IHC           score \> 6           OS
  Shuhua Zhao-13             2013    China                   Ovarian cancer                            I--IV                      146                  52.8y (26--79y)                 36m (7--82m)                  IHC             score ≥ 4         OS, PFS
  Ying Liu-34                2013    China                    Breast cancer                           I--III                      189                        NA                             NA                       IHC                ≥10%              OS
  Anja Rabien-35             2013   Germany               Renal cell carcinoma                        pN0/M0                      181                   60y (21--86y)                 112m (0--194m)               TMA/IHC           score ≥ 1            OS
  Xiaoyan Xu-36              2013    China                Non-small lung cancer                        I--IV                      136                   60y (35--82y)                  28m (1--87m)                  IHC                ≥1%               OS
  Min Yang-37                2013    China                    Glioblastoma                              NA                        206                  53.6y (14--78y)               12.3 m (1--60 m)                IHC             score ≥ 1            OS
  Yang Zhao-14               2013    China                 Ovarian carcinomas                          I--IV                      88                   51.2y (20--81y)                 52m (1--103m)               TMA/IHC           score ≥ 1         RFS, OS
  Qiang Lu-17                2013    China                    Osteosarcoma                           IIA--III                     55                         NA                        32m (8--72m)                  IHC                ≥5%               OS
  Dake Chu-38                2014    China                   Gastric cancer                           T1--T4                      223                        NA                   41.8m (DFS)/58.0m (OS)             IHC                ≥5%            OS, PFS
  Qin Xu-39                  2014    China                 Cervical carcinoma                        Ia1--IIb                     110                        NA                             NA                       IHC                ≥10%           OS, PFS
  Shu Zhao-40                2014    China                    Breast cancer                           I--III                      127                   49y (30--68y)                       NA                       IHC                ≥10%           OS, PFS
  Naohisa Futamura-16        2014    Japan                    Osteosarcoma                           IIA--IIB                     53                    20y (4--57y)                   72m (8--200m)                 IHC             score ≥ 1         OS, DFS
  Jian Gao-43                2014    China                   Ovarian cancer                            I--IV                      92                         NA                             NA                       IHC                ≥5%               OS
  Luís Silva Monteiro-15     2014   Portugal          Oral squamous cell carcinomas                    I--IV                      74               62.3 ± 15.3y (25--96y)              36.45 ± 31.7m               TMA/IHC           score \> 3          CSS
  Shaojun Zhu-41             2015    China              Hepatocellular carcinoma                        NA                        50                       31--76y                          4y                       IHC                ≥5%               OS

###### Characteristics of studies exploring the relationship between CD147/EMMPRIN expression and tumor prognosis (Univariate model) V.

  Author                   Year   Country                 Cancer type                 Stage/grade    Number        Age Median (range)      Follow-up time Median (range)   Detection method     Cut-off      Outcome
  ----------------------- ------ ---------- ---------------------------------------- ------------- ----------- -------------------------- ------------------------------- ------------------ -------------- ---------
  Hai-Gang Li-42           2005    China            Hepatocellular carcinoma           grade1--4       51          51 ± 11y (24--69y)              26m (5--90m)                  IHC              ≥10%         DFS
  Wen-Chiuan Tsai -43      2006    China              Renal cell carcinoma               I--IV         100                 NA                         5--year                  TMA/IHC        score \> 130     OS
  Nobuyuki Hakuma-44       2007    Japan          Non-Small Cell Lung Cancers           stage I        95              62.8 ± 9.1                      5--y                      IHC           score \> 3      OS
  Wen Chiuan Tsai-45       2007    China        Pancreatobiliary adenocarcinoma           T4           70                  NA                          2--y                      IHC          score \> 100     OS
  Wei Wu-46                2008    China             Gallbladder carcinoma               I--IV         108      51.63 ± 10.08y (35--76y)               5--9y                     IHC              ≥5%          OS
  Daniel Buergy-47         2009   Germany              Colorectal Cancer                 I--IV         40                  NA                        30 months                   IHC              ≥5%          DSS
  Ziming Du-48             2009    China            Nasopharyngeal carcinoma             I--IV         157           46y (14--86y)                     5--y                    TMA/IHC            ≥5%          OS
  Zhaodong Han-49          2010    China        Renal/Bladder/Prostate carcinoma         I--IV      52/58/101        57.26 ± 11.2y                     1--5y                     IHC              ≥5%          OS
  H. Z. Zeng-7             2011    China           Non-small-cell lung cancer           III/IV         118                 NA                           NA                       IHC              ≥25%         OS
  Congfa Huang-9           2012    China         Tongue squamous cell carcinoma          I--IV         80                  NA                      69m (2--106m)                 IHC              ≥10%         OS
  Larissa Sweeny-50        2012     USA        Cutaneous Squamous Cell Carcinoma        III--IV        56           72 ± 12 (42--91)                   \>2y                      IHC              ≥25%         OS
  Keiichiro Nakamura-51    2012    Japan               Endometrial cancer                I--IV         134           57.7y (28--85)                     NA                       IHC              ≥10%       DFS, OS
  Mototaka Sato-52         2013    Japan              Renal cell carcinoma               I--IV         50             27--82 (62)                  52 (1--114 m)                 IHC           score ≥ 1     OS, PFS
  Wen Chiuan Tsai-53       2013    China                  Astrocytomas                  III--IV        77                  NA                           NA                 GDS1962 database      1,500         OS
  Qing Yang-54             2013    China     Hypopharyngeal Squamous Cell Carcinoma      I--IV         80           60.73y (42--78)                                              IHC           ≥P90 level      RFS
  Xinwen Zhong-55          2013    China                  Lung cancer                     T1           180           60y (37--75y)                 60m (3--96m)                  IHC              ≥25%         OS
  Jung-Woo Choi-56         2014    Korea      Urothelial carcinoma of the bladder       Ta--T4         360           69y (23--97y)                      36m                    TMA/IHC        score \> 16      OS
  Xin-Qiong Huang-57       2014    China        Cervical squamous cell carcinoma        IB-IVA         132           51y (28--80y)                45m (2--85.5m)                 IHC              ≥5%          PFS
  Céline Pinheiro-58       2014   Portugal            Soft tissue sarcomas              I--III         84                  NA                           NA                       IHC           score ≥ 3       OS
  Younghye Kim-59          2015    Korea        Clear cell renal cell carcinoma          I--IV         180           25--83y (58y)                40.7m (1--173)               TMA/IHC        score \> 17      PFS

###### Relationship between CD147/EMMPRIN overexpression and clinical and pathological factors.

  Author                                     Cancer type                                      Relative to other factors                      Relative to clinicopathologic variables
  ------------------------- --------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Multivariate**                                                                                                                           
  Natalie Reimers-10                      Breast carcinoma                                        ER, PR (inversely)                         High tumor grade, histologically determined mitotic index, tumor size, inversely correlated to age
  HC Zheng-19                             Gastric carcinoma                                 ki-67, MMP-2, MMP-9, VEGF, MVD                   Tumour size, depth of invasion, lymphatic invasion, not with lymph node metastasis, UICC staging or differentiation
  Kazu Ueda-20                          Endometrial carcinoma                                                                                Advanced stage, poorly differentiated carcinoma, lymph node metastasis, lymphatic vessel infiltration, pathological high risk group
  Qing Zhang-21                       Hepatocellular carcinoma             MVD-CD34; MMP-2 in pericancerous, not in cancerous lesions; VEGF  pTNM tumor stages, tumor size and venous invasion, IV stage and large tumor size, preoperative AFP level; not: viral hepatitis, the number of tumor nodules, lymph node metastasis
  Anne B. Als-5                            Bladder Cancer                                                                                    Visceral metastases
  Wulf Sienel-22                     Non-small-cell lung cancer                                 MMP-2 (no), MMP-9 (no)                        
  Xingzhu Ju-23                            Cervical Cancer                                                                                   Pelvic lymph node metastasis, no correlation with clinical stage and histopathology
  Yu Li-11                                Breast carcinoma                                                                                    
  Fangfang Liu-12                         Breast carcinoma                                   C-erbB-2; ER, PR (inversely)                    Histological grade, local recurrence, distant metastasis and tumor mortality
  Xinjie Yang-24             Adenoid cystic carcinoma of salivary glands                 MMP-2, MMP-9, VEGF, Ki-67 index, MVD                Tumor size, histotypes, clinical stage, perneural invasion, vascular invasion, metastasis
  Wei-De Zhong-25                          Bladder cancer                                                                                    Tumor stage and grade, status of carcinoma *in situ*, tumor recurrence, tumor progression
  Tongwei Chu-26                      Pediatric Medulloblastoma                                                                              Higher metastatic stage, aggressive histopathological type, necrosis, undifferentiated tumor
  Yijun Xue-27                             Bladder cancer                                                                                    Lymph node status, tumor stage, histologic grade
  Shaojun Zhu-28                 Esophageal Squamous Cell Carcinoma                                                                          Lymph node metastasis cases, differentiation, depth of tumor invasion
  Weide Zhong-29                           Prostate cancer                                                                                   Gleason score, positive surgical margin status, reduced PSA failure-free survival
  Xuecheng Bi-30                           Human seminomas                                              MMP-2                                advanced T, N and M stage, poor differentiation types
  K Boye-31                               Colorectal cancer                                             S100A4                               no associations with any of the clinical or histopathological parameters
  Zhangxuan Shou-32                        Gastric Cancer                                               ADAM17                               Age, tumor size, location, depth of invasion, TNM stage, Lauren's classification, vessel invasion, and lymph node and distant metastasis of tumor
  Albrecht Stenzinger -33                 Colorectal cancer                                                                                  Trend correlation with stage, distant metastasis, blood vessel invasion, and Dukes classification
  Shuhua Zhao-13                           Ovarian cancer                                                                                    Lymph-vascular space involvement, lymph node metastasis
  Ying Liu-34                               Breast cancer                                                                                     
  Anja Rabien-35                        Renal cell carcinoma                                                                                 pT stage and Fuhrman grading
  Xiaoyan Xu-36                         Non-small lung cancer                                                                                Tumor diameter, lymph node status, tumor stage
  Min Yang-37                               Glioblastoma                                                                                     Karnofsky performance status (KPS) score
  Yang Zhao-14                           Ovarian carcinomas                                             Ki-67                                FIGO staging, dedifferentiation
  Qiang Lu-17                               Osteosarcoma                                                                                     Pathological classification, percentage of dead cells
  Dake Chu-38                              Gastric cancer                                                                                    Invasion, metastasis and TNM stage
  Qin Xu-39                              Cervical carcinoma                                                                                  FIGO clinical stage, lymph node metastasis, parametrium invasion, and differentiation
  Shu Zhao-40                               Breast cancer                                            MMP-9, Ki67                             Lymph node metastasis, high pathological grade, tumor size larger than 2 cm
  Naohisa Futamura-16                       Osteosarcoma                                               MT1-MMP                               Not associated with age, gender, anatomic location, necrosis after neoadjuvant chemotherapy, or surgical stage
  Jian Gao-43                              Ovarian cancer                                          Lewis y antigen                           Drug-resistant
  Luís Silva Monteiro-15            Oral squamous cell carcinomas                                       Ki-67                                Advanced tumor stages, histological grade
  Shaojun Zhu-41                      Hepatocellular carcinoma                                                                               No relationship between differentiation, HBV infection, significantly opposite to cirrhosis
  **Univariate**                                                                                                                             
  Hai-Gang Li-42                      Hepatocellular carcinoma                               paxillin and syndecan-1 (no)                    Not associated with serum AFP level, HBsAg status, presence of microsatellite nodule, tumor size, presence of cirrhosis and necrosis, differentiation, presence of portal vein thrombosis and extra-hepatic metastasis
  Wen-Chiuan Tsai -43                   Renal cell carcinoma                                            fascin                               Histological grades and clinical stages
  Nobuyuki Hakuma-44                 Non-Small Cell Lung Cancers                                                                             Well differentiated, not associated with any of the following variables: age, gender, histology, pT or pN classification, and pathological stage
  Wen Chiuan Tsai-45               Pancreatobiliary adenocarcinoma                                      fascin                               Histologic grades and clinical stages
  Wei Wu-46                             Gallbladder carcinoma                                           MMP-2                                Nevin stages of tumor tissues, histological differentiated degree, distant metastasis
  Daniel Buergy-47                        Colorectal Cancer                                                                                  pT or pN status, metastasis
  Ziming Du-48                        Nasopharyngeal carcinoma                                          Cav-1                                Metastasis of the disease
  Zhaodong Han-49                 Renal/Bladder/Prostate carcinoma                                                                           TNM stages, histological subtypes
  H. Z. Zeng-7                       Non-small-cell lung cancer                                                                              No association (overall CD147); (membranous CD147) associated with a poor response to chemotherapy
  Congfa Huang-9                   Tongue squamous cell carcinoma                            HIF-1a, VEGF-A, VEGF-C, CypA                    Recurrence and node metastasis
  Larissa Sweeny-50               Cutaneous Squamous Cell Carcinoma                                                                          Node positive disease
  Keiichiro Nakamura-51                  Endometrial cancer                                                                                  FIGO stage, histology, depth of myometrial invasion, cervical involvement, lymph node metastasis, lymph vascular space involvement, peritoneal cytology
  Mototaka Sato-52                      Renal cell carcinoma                                          anti-CD34                              Pathological T stage, clinical M stage, AJCC stage, Fuhrman grade, microvessel area of immature vessels
  Wen Chiuan Tsai-53                        Astrocytomas                                                                                     WHO grades
  Qing Yang-54                 Hypopharyngeal Squamous Cell Carcinoma                               CD44v6; COX-2                            T classification, lymph node metastasis and clinical stage
  Xinwen Zhong-55                            Lung cancer                                                RACK1                                Differentiation, Lymph node metastasis
  Jung-Woo Choi-56               Urothelial carcinoma of the bladder                                  MCT1, MCT4                             High World Health Organization grade, advanced tumor node metastatis stage, and nonpapillary growth type
  Xin-Qiong Huang-57              Cervical squamous cell carcinoma                                      GLUT-1                               Histopathological grade, Tumor diameter, radiation-resistant
  Céline Pinheiro-58                    Soft tissue sarcomas                                          MCT1, MCT4                             Disease progression
  Younghye Kim-59                  Clear cell renal cell carcinoma                                                                           High grade, tumor necrosis, larger tumor size

###### Meta-analysis of association between CD147/EMMPRIN expression and tumor prognosis.

                                      OS                       PFS                        DSS                                                                                                                                                    
  ------------------------ ------------------------ -------------------------- ------------------------- -------------------------- ------------------------- ------------------------- ------- ------------------------- -------------- --- --- ---
      **Multivariate**                                                                                                                                                                                                                           
         **Total**                 27/3933           1.92 (1.58--2.32) 0.000         66.4 (0.000)                 13/1845            2.32 (1.67--3.21) 0.000        56.3 (0.007)         4/991   1.83 (1.27--2.65) 0.001   0.00 (0.458)           
      **Solid tumor**              23/3563           1.73 (1.44--2.08) 0.000         60.7 (0.000)                 12/1792            2.26 (1.61--3.18) 0.000        58.5 (0.005)         4/991   1.83 (1.27--2.65) 0.001   0.00 (0.458)           
    **Nun-solid tumor**             4/370            3.72 (2.23--6.22) 0.000         36.6 (0.192)                   1/53             3.52 (1.18--10.5) 0.024                               0                                                     
      Breast carcinoma              5/695            2.92 (1.85--4.60) 0.000         5.00 (0.378)                  3/419             2.50 (1.63--3.83) 0.000        0.00 (0.846)                                                                 
       Bladder cancer               3/333            2.32 (1.63--3.29) 0.000         0.00 (0.860)                                                                                                                                                
     Gastric carcinoma              3/878            1.33 (0.99--1.80) 0.060         62.0 (0.072)                                                                                                                                                
     Colorectal cancer              2/527            2.14 (1.38--4.26) 0.035         77.9 (0.033)                                                                                                                                                
       Ovarian cancer               3/326            1.57 (1.23--2.01) 0.000         0.00 (0.982)                  2/234             1.72 (1.23--2.40) 0.002        0.00 (0.833)                                                                 
        Osteosarcoma                2/108            7.83 (3.18--19.27) 0.000        0.00 (0.852)                                                                                                                                                
   **Total publish bias**   **0.05 (Begg' test)**    **0.007 (Egger' test)**    **0.300 (Begg' test)**    **0.259 (Egger' test)**    **0.734 (Begg' test)**    **0.469 (Egger' test)**                                                           
       **Univariate**                                                                                                                                                                                                                            
           Total                   17/1880           1.98 (1.53--2.57) 0.000         89.3 (0.000)                  6/627             2.18 (1.30--3.63) 0.003        96.7 (0.000)         1/40    5.81 (4.16--7.46) 0.037                          
      **Solid tumor**              15/1719           2.06 (1.57--2.70) 0.000         90.4 (0.000)                  6/627             2.18 (1.30--3.63) 0.003        96.7 (0.000)         1/40    5.81 (4.16--7.46) 0.037                          
      Nun-solid tumor               2/161            1.34 (0.77--2.32) 0.300         2.90 (0.310)                    0                          0                                                                                                
    Renal cell carcinoma            3/202            1.87 (1.37--2.56) 0.000         70.9 (0.032)                  2/230             1.58 (1.34--1.85) 0.000         0.00 (0.91)                                                                 
        Lung Cancer                 3/393            1.16 (0.63--2.12) 0.630         74.1 (0.021)                   ---                        ---                                                                                               
     Bladder carcinoma              2/418            2.51 (1.46--4.33) 0.001         81.9 (0.019)                   ---                        ---                                                                                               
   **Total publish bias**   **0.773 (Begg' test)**   **0.228 (Egger' test)**    **−0.707 (Begg' test)**   **−0.304 (Egger' test)**                                                                                                               

P\* present P for HR, P\# present P for I2.

[^1]: These authors contributed equally to this work.
